首页ALTME • EPA
add
TME Pharma NV
市场资讯
财务信息
损益表
收入
净收入
| (EUR) | 2024年6月info | 年同比变化 |
|---|---|---|
收入 | — | — |
经营支出 | 136.85万 | -0.51% |
净收入 | -162.40万 | 11.23% |
净利润率 | — | — |
每股收益 | — | — |
息税折旧摊销前利润 | -133.55万 | 0.07% |
有效税率 | — | — |
资产负债表
总资产
负债总额
| (EUR) | 2024年6月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 270.30万 | -10.14% |
总资产 | 294.20万 | -15.02% |
负债总额 | 137.50万 | -62.07% |
权益总额 | 156.70万 | — |
发行在外的股份 | 4211.96万 | — |
市净率 | 3.68 | — |
资产回报率 | -116.29% | — |
资本回报率 | -217.64% | — |
现金流
现金净变动
| (EUR) | 2024年6月info | 年同比变化 |
|---|---|---|
净收入 | -162.40万 | 11.23% |
来自运营的现金 | -136.75万 | 19.42% |
投资现金 | -4000.00 | 57.89% |
融资现金 | 160.10万 | 78.88% |
现金净变动 | 22.90万 | 128.17% |
自由现金流 | -72.31万 | 3.18% |
简介
TME Pharma, formerly NOXXON Pharma, is a biotechnology company founded in 1997 in Berlin, Germany which specialises on cancer treatment by targeting the tumor microenvironment. TME Pharma N.V. is listed on Euronext Growth, Paris and is a member of the German Association of Research-Based Pharmaceutical Companies, Verband forschender Arzneimittelhersteller.
TME Pharma develops drugs using technology yielding L-RNA molecules, which are of mirror-image configuration compared to naturally occurring D-RNA molecules. The company calls these agents Spiegelmers, from Spiegel, the German word for "mirror."
The L-RNA are resistant to the natural RNA nuclease enzymes. Wikipedia
CEO
成立时间
1997
员工数量
13
